Krystal Biotech (KRYS) Change in Receivables (2023 - 2026)
Krystal Biotech (KRYS) posted quarterly Change in Receivables of $12.0 million for Q2 2026, up 46.39% year-over-year from $8.2 million in Q2 2025, and up 20743.1% on a QoQ basis from -$58000.0 in Q1 2026.
Krystal Biotech (KRYS) Change in Receivables (2023 - 2026) Analysis & Trends
Krystal Biotech has reported Change in Receivables for 4 years, with the latest figure at $12.0 million in Q2 2026.
- Change in Receivables for Q2 2026 came in at $12.0 million, up 46.39% year-over-year; the trailing twelve-month figure through Jun 2026 was $27.3 million (up 233.37% YoY), and the FY2025 annual result was $22.1 million, down 64.72% from the prior year.
- Change in Receivables climbed to $12.0 million in Q2 2026, from -$58000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $56.8 million in Q2 2024 and troughed at -$5.9 million in Q3 2024.
- A 4-year average of $11.6 million and a median of $7.8 million in 2024 frame the typical range for Change in Receivables.
- The widest annual swing landed in 2024, when Change in Receivables tumbled 163.75%; it then surged 401.78% in 2025.
- A 4-year view of Change in Receivables shows it stood at $32.7 million in 2023, then tumbled by 77.24% to $7.4 million in 2024, then slumped by 133.45% to -$2.5 million in 2025, then surged by 580.46% to $12.0 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $12.0 million in Q2 2026, -$58000.0 in Q1 2026, and -$2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 11.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.97 Mn |
| Jun 30, 2026 | 11.97 Mn |
| Mar 31, 2026 | -58,000.00 |
| Mar 31, 2026 | -58,000.00 |
| Dec 31, 2025 | -2.49 Mn |
| Dec 31, 2025 | -2.49 Mn |
| Sep 30, 2025 | 17.92 Mn |
| Sep 30, 2025 | 17.92 Mn |
| Jun 30, 2025 | 8.18 Mn |
| Jun 30, 2025 | 8.18 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Dec 31, 2024 | 7.45 Mn |
| Dec 31, 2024 | 7.45 Mn |
| Sep 30, 2024 | -5.94 Mn |
| Sep 30, 2024 | -5.94 Mn |
| Jun 30, 2024 | 56.77 Mn |
| Jun 30, 2024 | 56.77 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Mar 31, 2024 | 4.43 Mn |